PVP Ventures Acquires Rs 1.27 Billion Stake in 7Med

29 Aug 2025 CW Team

The transaction, valued at Rs 1.27 billion, involves a mix of primary and secondary stake purchases. This investment aligns with PVP's ambition to build a new-age global healthcare services platform focused on illness, wellness, and care.

Founded by leading nephrology and urology specialists, 7Med operates 22 dialysis centres—both standalone and within hospitals—across six Indian states. It also runs four super-speciality hospitals with a focus on renal care. The company, headquartered in Delhi NCR, employs over 450 professionals and has conducted over one million dialysis procedures to date.

7Med reported an EBITDA of approximately Rs 100 million for FY25, and with PVP’s infusion, aims to scale this to Rs 500 million over the next four years. Expansion plans include broadening its presence in Tier 2 and Tier 3 cities and significantly upgrading local healthcare infrastructure.

Mr Gaurav Davda, Head of M&A and Strategy at PVP, emphasised that the acquisition marks a pivotal step in creating a trusted healthcare brand network tailored to emerging markets. Dr Vijay Kher, Chairman of Epitome Hospitals, added that the partnership would enhance operational efficiency and accelerate access to quality kidney care across geographies.

PVP Ventures, traditionally rooted in real estate, is now actively diversifying through acquisitions. It has partnered with Brigade Enterprises and Casagrand to monetise legacy real estate assets, expecting over Rs 20 billion in cash flows over the next six years, which will be channelled into its healthcare ambitions.

With this deal, PVP Ventures positions itself as a major player in India’s healthcare transformation, targeting both impact and scale in a rapidly growing sector.

PVP Ventures Limited has announced the acquisition of a significant stake in 7Med India Pvt Ltd and Epitome Group of Hospitals, marking a strategic expansion into the healthcare sector. The Board has approved the purchase of an initial 41.2 per cent stake, with a clear roadmap to majority ownership within 12 months and an eventual increase to 76 per cent.The transaction, valued at Rs 1.27 billion, involves a mix of primary and secondary stake purchases. This investment aligns with PVP's ambition to build a new-age global healthcare services platform focused on illness, wellness, and care.Founded by leading nephrology and urology specialists, 7Med operates 22 dialysis centres—both standalone and within hospitals—across six Indian states. It also runs four super-speciality hospitals with a focus on renal care. The company, headquartered in Delhi NCR, employs over 450 professionals and has conducted over one million dialysis procedures to date.7Med reported an EBITDA of approximately Rs 100 million for FY25, and with PVP’s infusion, aims to scale this to Rs 500 million over the next four years. Expansion plans include broadening its presence in Tier 2 and Tier 3 cities and significantly upgrading local healthcare infrastructure.Mr Gaurav Davda, Head of M&A and Strategy at PVP, emphasised that the acquisition marks a pivotal step in creating a trusted healthcare brand network tailored to emerging markets. Dr Vijay Kher, Chairman of Epitome Hospitals, added that the partnership would enhance operational efficiency and accelerate access to quality kidney care across geographies.PVP Ventures, traditionally rooted in real estate, is now actively diversifying through acquisitions. It has partnered with Brigade Enterprises and Casagrand to monetise legacy real estate assets, expecting over Rs 20 billion in cash flows over the next six years, which will be channelled into its healthcare ambitions.With this deal, PVP Ventures positions itself as a major player in India’s healthcare transformation, targeting both impact and scale in a rapidly growing sector.

Infrastructure Urban

05 Nov 2025

TBO Tek Q2 Profit Climbs 12%, Revenue Surges 26% YoY

TBO Tek Limited one of the world’s largest travel distribution platforms, reported a solid performance for Q2 FY26 with a 26 per cent year-on-year increase in revenue to Rs 5.68 billion, reflecting broad-based growth and improving profitability.The company recorded a Gross Transaction Value (GTV) of Rs 8,901 crore, up 12 per cent YoY, driven by strong performance across Europe, MEA, and APAC regions. Adjusted EBITDA before acquisition-related costs stood at Rs 1.04 billion, up 16 per cent YoY, translating into an 18.32 per cent margin compared to 16.56 per cent in Q1 FY26. Profit after tax r..

Infrastructure Energy

05 Nov 2025

Northern Graphite, Rain Carbon Secure R&D Grant for Greener Battery Materials

Northern Graphite Corporation and Rain Carbon Canada Inc, a subsidiary of Rain Carbon Inc, have jointly received up to C$860,000 (€530,000) in funding under the Canada–Germany Collaborative Industrial Research and Development Programme to develop sustainable battery anode materials.The two-year, C$2.2 million project aims to transform natural graphite processing by-products into high-performance, battery-grade anode material (BAM). Supported by the National Research Council of Canada Industrial Research Assistance Programme (NRC IRAP) and Germany’s Federal Ministry for Economic Affairs a..

Infrastructure Urban

05 Nov 2025

Antony Waste Q2 Revenue Jumps 16%; Subsidiary Wins Rs 3,200 Cr WtE Projects

Antony Waste Handling Cell Limited (AWHCL), a leading player in India’s municipal solid waste management sector, announced a 16 per cent year-on-year increase in total operating revenue to Rs 2.33 billion for Q2 FY26. The growth was driven by higher waste volumes, escalated contracts, and strong operational execution.EBITDA rose 18 per cent to Rs 570 million, with margins steady at 21.6 per cent, while profit after tax stood at Rs 173 million, up 13 per cent YoY. Revenue from Municipal Solid Waste Collection and Transportation (MSW C&T) reached Rs 1.605 billion, and MSW Processing re..